Compare · GILD vs MAZE
GILD vs MAZE
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 127.8x MAZE ($1.53B).
- MAZE has been more active in the news (6 items in the past 4 weeks vs 5 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 8 for MAZE).
- Company
- Gilead Sciences Inc.
- Maze Therapeutics Inc.
- Price
- $156.22-0.76%
- $27.53+0.20%
- Market cap
- $195.13B
- $1.53B
- 1M return
- +3.48%
- -
- 1Y return
- +26.88%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2025
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 8
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest MAZE
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
- Chief Executive Officer Coloma Jason V sold $932,260 worth of shares (34,501 units at $27.02) as part of a pre-agreed trading plan (SEC Form 4)
- President, R&D & CMO Bernstein Harold exercised 16,141 shares at a strike of $10.42 and sold $434,743 worth of shares (16,141 units at $26.93) as part of a pre-agreed trading plan (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $202,921 worth of shares (7,500 units at $27.06) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- Citigroup initiated coverage on Maze Therapeutics with a new price target
- President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- GC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)